WARS2 Antibody

Code CSB-PA025966GA01HU
Size $600
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
WARS2
Alternative Names
WARS2 antibody; Tryptophan--tRNA ligase antibody; mitochondrial antibody; EC 6.1.1.2; antibody; Mt)TrpRS antibody; Tryptophanyl-tRNA synthetase antibody; TrpRS antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Human WARS2
Immunogen Species
Homo sapiens (Human)
Isotype
IgG
Purification Method
Antigen Affinity purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
PBS with 0.1% Sodium Azide, 50% Glycerol, pH 7.3. -20°C, Avoid freeze / thaw cycles.
Tested Applications
ELISA,WB
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Mitochondrial aminoacyl-tRNA synthetase that activate and transfer the amino acids to their corresponding tRNAs during the translation of mitochondrial genes and protein synthesis.
Gene References into Functions
  1. An alternative conformation of human TrpRS suggests a role of zinc in activating non-enzymatic function. PMID: 28910573
  2. The data demonstrate a pro-angiogenic function for Wars2 both within and outside the heart. PMID: 27389904
  3. This confidently implicates that mutations in WARS2 cause mitochondrial disease with a broad spectrum of clinical presentation. PMID: 28905505
  4. we found a compound heterozygous genotype of the mitochondrial tryptophanyl-tRNA synthetase (WARS2) gene, comprising a nonsense mutation (c.325delA, p.Ser109Alafs*15), which very likely entails nonsense-mediated mRNA decay and a missense mutation PMID: 28236339
  5. Here we substantially extend and consolidate the symptomatology of WARS2 by presenting a patient with severe infantile-onset leukoencephalopathy, profound intellectual disability, spastic quadriplegia, epilepsy, microcephaly, short stature, failure to thrive, cerebral atrophy, and periventricular white matter abnormalities PMID: 28650581
  6. first genome-wide scan for selection in Inuit from Greenland. A region, with a deeply divergent haplotype that is closely related to the sequence in the Denisovan genome contains two genes, WARS2 and TBX15. our study suggests a complex multi-factorial regulation of TBX15 and WARS2. We show that the introgressed region is associated with regional changes in methylation and expression levels PMID: 28007980
  7. tandem promoters provide a dual system to regulate expression and alternative splicing of human TrpRS in vivo PMID: 14757836
  8. Mutations located at the appended beta1-beta2 hairpin and the AIDQ sequence of human TrpRS switch this enzyme to a tRNA-dependent mode in the tryptophan activation step. PMID: 17726052

Show More

Hide All

Involvement in disease
Neurodevelopmental disorder, mitochondrial, with abnormal movements and lactic acidosis, with or without seizures (NEMMLAS)
Subcellular Location
Mitochondrion matrix.
Protein Families
Class-I aminoacyl-tRNA synthetase family
Tissue Specificity
Brain.
Database Links

HGNC: 12730

OMIM: 604733

KEGG: hsa:10352

STRING: 9606.ENSP00000235521

UniGene: Hs.523506

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*